Please Wait...

CXCL8/IL8 // C-X-C motif chemokine 8 / Interleukin 8

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

CXCL8 was the first characterized chemokine and was initially named IL-8. CXCL8, expressed by activated Th17 helper cells, attracts and activates neutrophils cells (Walz et al., 1987).

CXCL8 bind two different receptors: CXCR1 and CXCR2. CXCR1 is specific for CXCL8 and CXCR2 binds also CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7. Under physiological conditions, CXCL8 exists as monomers and dimers and both forms bind the receptors but the monomeric forms have a better ability to induce CXCR1 phosphorylation, desensitization and internalization (whereas both forms induce these actions for CXCR2). Dimerization of CXCL8 is then implicated in the regulation of inflammatory response (Nasser et al., 2009).

 

CXCL8-IL8 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

Nasser, M.W., Raghuwanshi, S.K., Grant, D.J., Jala, V.R., Rajarathnam, K., and Richardson, R.M. (2009). Differential Activation and Regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J. Immunol. Baltim. Md 1950 183, 3425–3432.

Walz, A., Peveri, P., Aschauer, H., and Baggiolini, M. (1987). Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem. Biophys. Res. Commun. 149, 755–761.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @endpts: #FDA revises draft guidance on #raredisease drug R&D https://t.co/KaNVw54MDE by @ZacharyBrennan via @RAPSorg
Bioclinica (12 hours ago)
RT @PrimeVigilance: News and Press Release - Source @EMA_News now available monthly meeting highlights from #Pharmacovigilance #RiskAssessm…
Bioclinica (12 hours ago)
RT @FDA_Drug_Info: New #FDA Draft Guidance for Industry on Rare Diseases – Common Issues in Drug Development: https://t.co/yxaGyMB7hY. http…
Bioclinica (12 hours ago)
Looking to exercise DDDM in clinical trials? Get tips on obtaining, distilling and presenting data in our new white… https://t.co/NkGrS9JnG8
Bioclinica (14 hours ago)
Is your clinical study supply chain management solution increasing the risk of stock out? Ehsan Ramezani gives pers… https://t.co/YCfP3wCvK6
Bioclinica (Yesterday)
Bioclinica's Kate Adamczuk is presenting at #HAI2019 today! Details on this and other scientific findings at HAI… https://t.co/wDQr6ldfcS
Bioclinica (Yesterday)

Latest Blogs:

Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner